BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Thermo Fisher Scientific, NSG BIO collaborate to strengthen Singapore's biotech startup ecosystem

April 9, 2025 | News | By Hithaishi C Bhaskar

The collaboration aims to provide advanced resources and scientific expertise to accelerate innovation and drive sustainable growth



Thermo Fisher Scientific Inc, the world leader in serving science, has signed a strategic Memorandum of Understanding (MoU) with NSG BIO, Singapore's largest BSL-2-certified, co-working laboratory and office space. This collaboration aims to empower biotech startups in Singapore with access to critical resources, advanced laboratory solutions, and scientific expertise to accelerate their research and development capabilities.

Since 2019, NSG BIO has supported innovators create impactful solutions across health, biomedical, agrifood, and industrial biotechnology sectors. Their work spans precision medicine, AI-enabled drug discovery, and synthetic biology. This partnership enables Thermo Fisher and NSG BIO to support research efficiency, accelerate innovation, and advance local healthcare and life sciences capabilities, aligning with national efforts to strengthen the sectors.

"We are excited to collaborate with NSG BIO to support Singapore's growing biotech ecosystem," said Sho-Wen Yeo, Vice President and General Manager, Southeast Asia & Taiwan, Thermo Fisher Scientific. "By ensuring seamless access to cutting-edge instruments and essential consumables, we enable scientists to focus on their critical research without operational challenges. This collaboration underscores our commitment to advancing scientific innovation and supporting the biotech community in Singapore."

"This strategic collaboration with Thermo Fisher Scientific marks a major milestone in our mission to drive biotech innovation in Singapore," said Daphne Teo, Founder and Chairwoman of NSG BIO. "By providing our residents with preferential access to world-class laboratory equipment and supplies, along with flexible credit terms, we are eliminating critical barriers that often hinder early-stage research. This collaboration reinforces our commitment to building a thriving biotech ecosystem where startups can accelerate breakthrough discoveries."